ZIOPHARM Oncology, Inc. (WEK.F)

1.4100 0.0000 (0.00%) As of 08:10AM CEST. Market open.

ZIOPHARM Oncology, Inc.

2617 Bissonnet Street
Suite 225
Houston, TX 77005
United States
346 355 4099
https://www.alaunos.com

Sector(s): 
Industry: 
Full-time employees: 1

Description

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Corporate governance

ZIOPHARM Oncology, Inc.’s ISS governance QualityScore as of 1 May 2024 is 6. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 3; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.